Prioritizing mutational profiling for targeted therapy of lung adenocarcinoma
Loading...
Files
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
AME Publishing Company
Abstract
Description
Keywords
B raf kinase, Cabozantinib, Capmatinib, Carcinogen, Crizotinib, Epidermal growth factor receptor 2, Erlotinib, K ras protein, Mammalian target of rapamycin complex 1, Mammalian target of rapamycin complex 2, Microtubule associated protein 2, Mitogen activated protein kinase kinase 2, Monoclonal antibody, Onartuzumab, Phosphatidylinositol 3 kinase, Phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase, Programmed death 1 ligand 1, Protein kinase b, Protein kinase lkb1, Protein p53, Protein tyrosine kinase inhibitor, Ras protein, Scatter factor receptor, T lymphocyte receptor, Tumor antigen, Vasculotropin receptor, Antineoplastic activity, Cancer diagnosis, Cancer immunotherapy, Cancer prognosis, Cancer survival, Clinical assessment, Clinical outcome, Clinical trial (topic), Comparative study, Disease association, Disease exacerbation, Drug sensitivity, Drug targeting, Evidence based practice, Follow up, Gene expression profiling, Gene mutation, Gene overexpression, Genome analysis, Genotype, Health care quality, Human, Immune evasion, Immune response, Immune system, Immunohistochemistry, Lung adenocarcinoma, Lung cancer, Molecularly targeted therapy, Mutation rate, Non small cell lung cancer, Overall survival, Patient selection, Personalized medicine, Preliminary data, Protein expression, Protein processing, Review, Sequence analysis, Signal transduction, Smoking, Somatic mutation, Treatment response, Tumor associated leukocyte, Tumor immunogenicity